People with type 2 diabetes starting semaglutide have more than a doubled risk for nonarteritic anterior ischemic optic neuropathy (NAION) versus those starting sodium-glucose cotransporter-2 inhibitors (SGLT2is), according to a brief report published online Feb. 12 in JAMA Ophthalmology.
Continue Reading this article here
